Wyeth extends its collaboration with Zealand Pharma  

The Danish biotech company and US based Wyeth will extend their current collaboration to involve drug development for the treatment of cardiovascular diseases

The Danish biotech company Zealand Pharma and US pharmaceutical company Wyeth are extending their current collaboration which started at the beginning of 2003. The new cooperation concerns drug development for the treatment of cardiovascular diseases, with Wyeth paying all costs involved. If the cooperation is successful both parties expect to further extend it in 2005. The news is reported by BiotechDenmark on line.


Zealand Pharma was founded in 1998 and located in Glostrup, near Copenhagen. The biotech company's drug discovery platform combines a unique position in gap junction modulation with peptide modification expertise which includes Structure Inducing Probe technology. Zealand aims at discovering and developing novel drugs with significant therapeutic improvement.


Link > Zealand Pharma 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×